[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100623364":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":31,"centralContacts":26,"locations":36,"responsibleParty":53,"collaborators":26,"id":57,"slug":58,"hasResults":59,"nctId":60,"briefTitle":61,"officialTitle":62,"acronym":63,"eligibilityCriteria":64,"healthyVolunteers":59,"sex":65,"minAge":66,"maxAge":26,"enrollmentInfo":67,"targetDuration":26,"studyType":70,"phases":71,"briefSummary":73,"conditions":74,"keywords":79,"overallStatus":84,"whyStopped":26,"lastUpdateSubmitDate":85,"lastUpdatePostDateStruct":86,"startDateStruct":89,"completionDateStruct":91,"leadSponsor":93,"locationsCount":94},{"fullName":5,"class":6},"Ordu University","OTHER",[8,15],{"label":9,"type":10,"description":11,"interventionNames":12},"Intervention Group","EXPERIMENTAL","Participants in this group will receive standard wound care plus perilesional subcutaneous dexpanthenol injections administered at predefined intervals according to a standardized protocol.",[13,14],"Drug: Dexpanthenol","Other: Standard Wound Care",{"label":16,"type":17,"description":18,"interventionNames":19},"Control Group","ACTIVE_COMPARATOR","Participants in this group will receive standardized wound care alone without subcutaneous dexpanthenol administration.",[14],[21,27],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DRUG","Dexpanthenol","Dexpanthenol will be administered by perilesional subcutaneous injection around the wound area in addition to standard wound care. The injection dose and volume will be standardized according to wound size, with a limited number of treatment sessions.",[9],null,{"type":6,"name":28,"description":29,"armGroupLabels":30,"otherNames":26},"Standard Wound Care","Standard wound care includes wound cleansing with saline solution and topical wound management according to institutional protocols.",[16,9],[32],{"name":33,"affiliation":34,"role":35},"Dilara Canbay Özdemir, MD","Ordu University Faculty of Medicine, Department of Family Medicine","PRINCIPAL_INVESTIGATOR",[37],{"facility":38,"status":26,"city":39,"state":39,"zip":40,"country":41,"countryCode":26,"cosmosGeoPoint":42,"geoPoint":47,"contacts":48},"Ordu University Training and Research Hospital","Ordu","52200","Turkey (Türkiye)",{"type":43,"coordinates":44},"Point",[45,46],37.89047,40.97782,{"lat":46,"lon":45},[49],{"name":33,"role":50,"phone":51,"phoneExt":26,"email":52},"CONTACT","+905388147957","dilaracanbayozdemir@odu.edu.tr",{"type":54,"investigatorFullName":55,"investigatorTitle":56,"investigatorAffiliation":5,"oldNameTitle":26,"oldOrganization":26},"SPONSOR_INVESTIGATOR","Dilara CANBAY OZDEMIR","Assistant Professor of Family Medicine","100623364","subcutaneous-dexpanthenol-administration-and-wound-epithelialization-100623364",false,"NCT07395674","Subcutaneous Dexpanthenol Administration and Wound Epithelialization","Evaluation of the Effect of Subcutaneous Dexpanthenol Administration on Wound Epithelialization: A Pilot Randomized Controlled Study","DEXPAN-WOUND","Inclusion Criteria:\n\n* Adults aged 18 years and older.\n* Presence of a chronic wound, including diabetic foot ulcer, venous leg ulcer, or arterial ulcer.\n* Target wound size between 1 and 20 cm² at baseline.\n* Non-infected wound, defined by the absence of purulent discharge, foul odor, spreading erythema, cellulitis, or systemic signs of infection.\n* Clinically stable patients without the need for systemic antibiotic therapy.\n* Ability to understand the study procedures and provide written informed consent.\n* Willingness and ability to comply with study visits and treatment schedule.\n\nExclusion Criteria:\n\n* Clinical signs of wound infection or requirement for systemic antibiotic treatment.\n* Critical limb ischemia, defined as ankle-brachial index \\\u003C0.5, rest pain, gangrene, or extensive tissue necrosis.\n* Wounds exposing bone, tendon, or joint structures, or suspected osteomyelitis.\n* Wound size smaller than 1 cm² or larger than 20 cm².\n* Malignant, autoimmune, vasculitic, or specific dermatologic conditions causing the wound.\n* Known hypersensitivity or allergy to dexpanthenol or any component of the study treatments.\n* Pregnancy or breastfeeding.\n* Cognitive impairment or inability to provide informed consent.\n* Participation in another interventional clinical trial that could interfere with the outcomes of this study.\n* Any medical condition that, in the investigator's judgment, could compromise participant safety or study integrity.","ALL","18 Years",{"count":68,"type":69},40,"ESTIMATED","INTERVENTIONAL",[72],"NA","Chronic wounds are wounds that do not heal properly over time and can significantly reduce quality of life. Common types include diabetic foot ulcers, venous leg ulcers, and arterial ulcers. Improving wound healing and speeding up skin regeneration (epithelialization) are important goals in the care of these patients.\n\nDexpanthenol is a vitamin B5 derivative that supports skin repair and tissue regeneration. It is widely used in topical treatments, and injectable forms are approved for clinical use. However, the effects of subcutaneous (under the skin) dexpanthenol injections on chronic wound healing have not been sufficiently studied in clinical settings.\n\nThe purpose of this study is to evaluate whether adding subcutaneous dexpanthenol injections to standard wound care improves wound healing compared with standard wound care alone. Adult patients with non-infected chronic wounds will be randomly assigned to one of two groups. One group will receive standard wound care only, while the other group will receive standard wound care plus subcutaneous dexpanthenol injections around the wound area.\n\nWound healing will be assessed by measuring changes in wound size and the degree of skin epithelialization over time using standardized and objective methods. Safety will be monitored by recording local reactions at the injection site and any other adverse events during the study.\n\nThe results of this study may provide preliminary clinical evidence on the effectiveness and safety of subcutaneous dexpanthenol as an additional treatment option for chronic wound management.",[75,76,77,78],"Chronic Wounds","Diabetic Foot Ulcer","Venous Leg Ulcers","Arterial Ulcer",[23,75,80,81,76,82,78,83],"Wound Healing","Epithelialization","Venous Leg Ulcer","Randomized Controlled Trial","NOT_YET_RECRUITING","2026-04-16",{"date":87,"type":88},"2026-04-21","ACTUAL",{"date":90,"type":69},"2026-08-02",{"date":92,"type":69},"2028-12-02",{"name":55,"class":6},1]